Replimune Group, Inc. 8-K

What Happened
Replimune Group, Inc. announced on May 29, 2026 that, following collaborative communications with the U.S. Food and Drug Administration, it will resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. The company furnished a news release about the resubmission as Exhibit 99.1 to its Form 8-K.

Key Details

• Date of disclosure: May 29, 2026 (Form 8-K Item 7.01, Regulation FD Disclosure).
• Product: RP1 (vusolimogene oderparepvec) intended to be used with nivolumab (a PD-1 inhibitor).
• Action: Company will resubmit its BLA to the FDA after collaborative communications.
• Announcement documented in a news release (Exhibit 99.1 to the 8-K).

Why It Matters
A BLA resubmission is a major regulatory milestone toward potential FDA approval and future commercialization; approval could affect Replimune’s future revenue prospects for treating advanced melanoma. The filing indicates ongoing, constructive engagement with the FDA, but the Form 8-K does not provide a timeline or outcome — investors should watch for follow-up regulatory updates, review outcomes of the resubmission, and consider regulatory risk when assessing the company.